AirDuo RespiClick

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
AirDuo RespiClick
Generic name
FLUTICASONE PROPIONATE AND SALMETEROL
Manufacturer
Teva Respiratory, LLC
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
9c122b91-a11f-49ca-80bb-3eec5112db87
SPL ID
e8df87d3-fa81-4e19-9cd8-429a5f900395
Version
17
Effective date
2021-07-31
Source export date
2026-11-13
Source partition
2
Source file
https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/3b4204ed830f35b16ab24b2123672d7d93066eb0fd8af1cf09b223d0e4568221/drug-label-0002-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 15:32:06
Harmonized routes table
Harmonized routes
RESPIRATORY (INHALATION)

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 2 of 5 · 20 matching rows.

warnings and cautions

5.4 Oropharyngeal Candidiasis In clinical trials, the development of localized infections of the mouth and pharynx with Candida albicans has occurred in subjects treated with AIRDUO RESPICLICK. When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while treatment with AIRDUO RESPICLICK continues, but at times therapy with AIRDUO RESPICLICK may need to be interrupted. Advise the patient to rinse his/her mouth with water without swallowing following inhalation to help reduce the risk of oropharyngeal candidiasis.

warnings and cautions

5.5 Immunosuppression and Risk of Infections Persons who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible adolescents or adults using corticosteroids. In such patients who have not had these diseases or who have not been properly immunized, particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If a patient is exposed to chickenpox, prophylaxis with varicella-zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG) may be indicated. If a patient is exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chickenpox develops, treatment with antiviral agents may be considered. Inhaled corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infections of the respiratory tract; systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.

warnings and cautions

5.6 Transferring Patients from Systemic Corticosteroid Therapy HPA Suppression/Adrenal Insufficiency Particular care is needed for patients who are transferred from systemically active corticosteroids to inhaled corticosteroids because deaths due to adrenal insufficiency have occurred in patients with asthma during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. After withdrawal from systemic corticosteroids, a number of months are required for recovery of hypothalamic‑pituitary‑adrenal (HPA) function. Patients who have been previously maintained on 20 mg or more of prednisone (or its equivalent) may be most susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn. During this period of HPA suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to trauma, surgery, or infection (particularly gastroenteritis) or other conditions associated with severe electrolyte loss. Although AIRDUO RESPICLICK may improve control of asthma symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of corticosteroid systemically and does NOT provide the mineralocorticoid activity that is necessary for coping with these emergencies. During periods of stress or a severe asthmatic attack, patients who have been withdrawn from systemic corticosteroids should be instructed to resume oral corticosteroids (in large doses) immediately and to contact their physician for further instruction. These patients should also be instructed to carry a medical identification warning card indicating that they may need supplementary systemic corticosteroids during periods of stress or a severe asthma attack. Patients requiring systemic corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to AIRDUO RESPICLICK. Lung function (mean forced expiratory volume in 1 second [FEV 1 ] or morning peak expiratory flow [AM PEF]), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of systemic corticosteroids. In addition to monitoring asthma signs and symptoms, patients should be observed for signs and symptoms of adrenal insufficiency, such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension. Unmasking of Allergic Conditions Previously Suppressed by Systemic Corticosteroids Transfer of patients from systemic corticosteroid therapy to AIRDUO RESPICLICK may unmask allergic conditions previously suppressed by the systemic corticosteroid therapy (e.g., rhinitis, conjunctivitis, eczema, arthritis, eosinophilic conditions). Corticosteroid Withdrawal Symptoms During withdrawal from oral corticosteroids, some patients may experience symptoms of systemically active corticosteroid withdrawal (e.g., joint and/or muscular pain, lassitude, depression) despite maintenance or even improvement of respiratory function.

warnings and cautions

5.7 Hypercorticism and Adrenal Suppression Fluticasone propionate, a component of AIRDUO RESPICLICK, will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. Since fluticasone propionate is absorbed into the circulation and can be systemically active at higher doses, the beneficial effects of AIRDUO RESPICLICK in minimizing HPA dysfunction may be expected only when recommended dosages are not exceeded and individual patients are titrated to the lowest effective dose. A relationship between plasma levels of fluticasone propionate and inhibitory effects on stimulated cortisol production has been shown after 4 weeks of treatment with fluticasone propionate inhalation aerosol. Since individual sensitivity to effects on cortisol production exists, physicians should consider this information when prescribing AIRDUO RESPICLICK. Because of the possibility of significant systemic absorption of inhaled corticosteroids, patients treated with AIRDUO RESPICLICK should be observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response. It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients who are sensitive to these effects. If such effects occur, AIRDUO RESPICLICK should be reduced slowly, consistent with accepted procedures for reducing systemic corticosteroids, and for management of asthma symptoms.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Serious asthma-related events – hospitalizations, intubations, death [see Warnings and Precautions ( 5.1 )] Oropharyngeal candidiasis [see Warnings and Precautions ( 5.4 )] Immunosuppression and risk of infections [see Warnings and Precautions ( 5.5 )] Hypercorticism and adrenal suppression [see Warnings and Precautions ( 5.7 )] Cardiovascular and central nervous system effects [see Warnings and Precautions ( 5.11 )] Reduction in bone mineral density [see Warnings and Precautions ( 5.12 )] Growth effects in pediatrics [see Warnings and Precautions ( 5.13 )] Glaucoma and cataracts [see Warnings and Precautions ( 5.14 )] Most common adverse reactions (greater than or equal to 3%): nasopharyngitis, oral candidiasis, headache, cough and back pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience in Asthma Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In two placebo-controlled, 12-week, clinical studies (Trials 1 and 2) [see Clinical Studies ( 14 )] , a total of 1,364 adolescent and adult patients with persistent symptomatic asthma despite ICS or ICS/LABA therapy were treated twice daily with either placebo; fluticasone propionate MDPI 55 mcg, 113 mcg, or 232 mcg (ARMONAIR RESPICLICK, hereafter referred to as fluticasone propionate MDPI); or AIRDUO RESPICLICK 55 mcg/14 mcg, 113 mcg/14 mcg, or 232 mcg/14 mcg. Sixty percent of patients were female and 80% of patients were white. The average duration of exposure was 82 to 84 days in the fluticasone propionate MDPI and AIRDUO RESPICLICK treatment groups compared with 75 days in the placebo group. Table 2 displays the incidence of most common adverse reactions in pooled Trials 1 and 2. Table 2: Adverse Reactions with ≥3% Incidence with AIRDUO RESPICLICK, and More Common than Placebo in Subjects with Asthma (Trials 1 and 2) Adverse Reaction Fluticasone Propionate MDPI55 mcg (n=129)% Fluticasone Propionate MDPI113 mcg (n=274)% Fluticasone Propionate MDPI232 mcg (n=146)% AIRDUO RESPICLICK 55 mcg/14 mcg (n=128)% AIRDUO RESPICLICK 113 mcg/14 mcg (n=269)% AIRDUO RESPICLICK 232 mcg/14 mcg (n=145)% Placebo (n=273)% Nasopharyngitis 5.4 5.8 4.8 8.6 4.8 6.9 4.4 Oral candidiasis* 3.1 2.9 4.8 1.6 2.2 3.4 0.7 Headache 1.6 7.3 4.8 5.5 4.8 2.8 4.4 Cough 1.6 1.8 3.4 2.3 3.7 0.7 2.6 Back pain 0 1.5 1.4 3.1 0.7 0 1.8 *Oral candidiasis includes oropharyngeal candidiasis, oral fungal infection, and oropharyngitis fungal Other adverse reactions not previously listed (and occurring in <3% of patients and in three or more patients on AIRDUO RESPICLICK) that were reported more frequently by patients with asthma treated with AIRDUO RESPICLICK compared with patients treated with placebo include the following: Sinusitis, oropharyngeal pain, pharyngitis, dizziness, influenza, rhinitis allergic, respiratory tract infection, rhinitis, nasal congestion, abdominal pain upper, myalgia, pain in extremity, dyspepsia, laceration, dermatitis contact, and palpitations. Long Term Safety Study: This was a 26-week, open labeled study of 674 patients previously treated with ICS who were treated twice daily with fluticasone propionate MDPI 113 mcg or 232 mcg; AIRDUO RESPICLICK 113 mcg/14 mcg or 232 mcg/14 mcg; fluticasone propionate inhalation aerosol 110 mcg or 220 mcg; fluticasone propionate and salmeterol inhalation powder (250 mcg/50 mcg), or fluticasone propionate and salmeterol inhalation powder (500 mcg/50 mcg). The types of adverse reactions were similar to those reported above in placebo-controlled studies. 6.2 Postmarketing Experience In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during post approval use of fluticasone propionate and/or salmeterol regardless of indication. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to fluticasone propionate and/or salmeterol or a combination of these factors. Cardiac Disorders : Arrhythmias (including atrial fibrillation, extrasystoles, supraventricular tachycardia), ventricular tachycardia. Endocrine Disorders : Cushing’s syndrome, Cushingoid features, growth velocity reduction in children/adolescents, hypercorticism. Eye Disorders : Glaucoma, blurred vision and central serous chorioretinopathy. Gastrointestinal Disorders : Abdominal pain, dyspepsia, xerostomia. Immune System Disorders : Immediate and delayed hypersensitivity reaction (including very rare anaphylactic reaction). Very rare anaphylactic reaction in patients with severe milk protein allergy. Infections and Infestations : Esophageal candidiasis. Metabolic and Nutrition Disorders : Hyperglycemia, weight gain. Musculoskeletal, Connective Tissue, and Bone Disorders : Arthralgia, cramps, myositis, osteoporosis. Nervous System Disorders : Paresthesia, restlessness. Psychiatric Disorders : Agitation, aggression, depression. Behavioral changes, including hyperactivity and irritability, have been reported very rarely and primarily in children. Reproductive System and Breast Disorders : Dysmenorrhea. Respiratory, Thoracic, and Mediastinal Disorders : Chest congestion; chest tightness, dyspnea; facial and oropharyngeal edema, immediate bronchospasm; paradoxical bronchospasm; tracheitis; wheezing; reports of upper respiratory symptoms of laryngeal spasm, irritation, or swelling such as stridor or choking. Skin and Subcutaneous Tissue Disorders : Ecchymoses, photodermatitis. Vascular Disorders : Pallor.

adverse reactions table

<table> <col/> <col/> <col/> <col/> <col/> <col/> <col/> <col/> <thead> <tr> <th align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">Adverse Reaction</th> <th align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">Fluticasone Propionate MDPI55 mcg (n=129)%</th> <th align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">Fluticasone Propionate MDPI113 mcg (n=274)%</th> <th align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">Fluticasone Propionate MDPI232 mcg (n=146)%</th> <th align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">AIRDUO RESPICLICK 55 mcg/14 mcg (n=128)%</th> <th align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">AIRDUO RESPICLICK 113 mcg/14 mcg (n=269)%</th> <th align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">AIRDUO RESPICLICK 232 mcg/14 mcg (n=145)%</th> <th align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">Placebo (n=273)%</th> </tr> </thead> <tbody> <tr> <td colspan="8" styleCode=" Toprule Lrule Rrule"> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Nasopharyngitis</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>5.4</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>5.8</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>4.8</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>8.6</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>4.8</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>6.9</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>4.4</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Oral candidiasis*</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>3.1</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2.9</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>4.8</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1.6</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2.2</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>3.4</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>0.7</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Headache</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1.6</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>7.3</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>4.8</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>5.5</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>4.8</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2.8</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>4.4</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Cough</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1.6</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1.8</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>3.4</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2.3</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>3.7</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>0.7</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2.6</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Back pain </paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>0</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1.5</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1.4</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>3.1</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>0.7</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>0</paragraph> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1.8</paragraph> </td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.